Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589734 | 0.84 | KMT2A (0.50) | KMT2AGSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL2831481 | 0.73 | ALDH1A1 (0.52) | KMT2AGSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL7082273 | 0.72 | ALDH1A1 (0.49) | KMT2AGSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL5180011 | 0.72 | ALDH1A1 (0.51) | GSK3AGSK3BALDH1A1KDM4EPIN1 | |
| SCHEMBL12636575 | 0.71 | FPR2 (0.46) | KMT2AGSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL2824950 | 0.71 | ALDH1A1 (0.50) | KMT2AGSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL3911656 | 0.71 | ALDH1A1 (0.50) | GSK3AGSK3BALDH1A1KDM4EPIN1 | |
| SCHEMBL12636573 | 0.71 | FPR2 (0.46) | KMT2AGSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL13115685 | 0.71 | LMNA (0.46) | KMT2AALDH1A1KDM4EPIN1PIN4 | |
| SCHEMBL21246876 | 0.70 | KMT2A (0.43) | KMT2AGSK3AGSK3BALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341784-A2 | PROCESS FOR MAKING A THROMBIN INHIBITOR | Merck & Co., Inc. (US) | 2003-09-10 | — | — | EP | claimed |
| US-20020103379-A1 | Process for making a thrombin inhibitor | MERCK SHARP & DOHME LTD. (GB) | 2002-08-01 | — | — | US | claimed |
| WO-2002046160-A2 | PROCESS FOR MAKING A THROMBIN INHIBITOR | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | claimed |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| US-7026324-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-04-11 | — | — | US | disclosed |
| WO-2005040137-A1 | AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20040097730-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2004-05-20 | — | — | US | disclosed |
| EP-1359913-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1341784-A2 | PROCESS FOR MAKING A THROMBIN INHIBITOR | Merck & Co., Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002064140-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20020103379-A1 | Process for making a thrombin inhibitor | MERCK SHARP & DOHME LTD. (GB) | 2002-08-01 | — | — | US | disclosed |
| WO-2002046160-A2 | PROCESS FOR MAKING A THROMBIN INHIBITOR | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103379-A1 | Process for making a thrombin inhibitor | TFPI, TFPI2, F2 | KMT2A 507/4885GSK3A 2840/4885GSK3B 3587/4885 |
| US-20040097730-A1 | Thrombin inhibitors | F3, F2, SERPINC1 | KMT2A 3143/4885GSK3A 2211/4885GSK3B 1826/4885 |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | F2, F12, SERPINC1 | KMT2A 3601/4885GSK3A 2042/4885GSK3B 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.